Mr. David Burke reports

SERNOVA ANNOUNCES KEY NEW EXECUTIVE APPOINTMENTS

Sernova Corp. has made key new appointments to its executive leadership team. This strategic move reflects Sernova's commitment to enhancing communication with stakeholders and corporate governance as the company drives its innovative research and continuing clinical development programs.

James Parsons has been named chief financial officer, bringing over 20 years of financial management experience to the team. With a comprehensive record in biotech corporate finance, governance and strategic planning, Mr. Parsons will lead Sernova's finance team and ensure the company's financial strength to support expanding objectives.

Joining as chief communications officer is Marylyn Rigby, an accomplished professional with a rich history in branding, corporate communications, and biotechnology and health technology marketing. Ms. Rigby will direct Sernova's comprehensive communication strategies, enhancing marketing initiatives, expanding media relationships, and elevating investor and stakeholder engagement, pivotal for bolstering Sernova's brand identity and outreach.

David Burke assumes the role of vice-president of investor relations, tasked with fortifying connections with the investment community. Bringing extensive experience in investor communications and financial markets, Mr. Burke will ensure transparent, timely and effective dialogue with current and prospective investors, building trust and fostering long-term support for Sernova's visionary projects.

Jonathan Rigby, chief executive officer of Sernova, expressed his enthusiasm for the appointments, stating: "We are thrilled to welcome James, Marylyn and David to our leadership team. Each brings a unique set of skills and deep industry knowledge that will be vital as we continue to advance our pipeline and expand our corporate presence. Their expertise aligns perfectly with our mission to give patients their lives back through our groundbreaking therapies."

These key appointments exemplify a step change in Sernova's unwavering commitment to excellence and innovation as it continues to drive forward novel treatments that aim to transform how chronic conditions are treated in order to improve the lives of patients, their families and their caregivers.

About Sernova Corp.

Sernova is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a biohybrid organ. A biohybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on Type 1 diabetes and thyroid disorders.

We seek Safe Harbor.